These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 22722025

  • 1. Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats.
    Smith GA, Breger LS, Lane EL, Dunnett SB.
    Neuropharmacology; 2012 Oct; 63(5):818-28. PubMed ID: 22722025
    [Abstract] [Full Text] [Related]

  • 2. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E, Lisci C, Tronci E, Fidalgo C, Stancampiano R, Björklund A, Carta M.
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [Abstract] [Full Text] [Related]

  • 3. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
    Iderberg H, Rylander D, Bimpisidis Z, Cenci MA.
    Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
    [Abstract] [Full Text] [Related]

  • 4. Amphetamine-induced rotation in the transplanted hemi-parkinsonian rat--response to pharmacological modulation.
    Smith GA, Dunnett SB, Lane EL.
    Behav Brain Res; 2012 Jul 01; 232(2):411-5. PubMed ID: 22516841
    [Abstract] [Full Text] [Related]

  • 5. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E, Garcia J, Winkler C, Björklund A, Carta M.
    Neurobiol Dis; 2012 Sep 01; 47(3):393-406. PubMed ID: 22579773
    [Abstract] [Full Text] [Related]

  • 6. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
    Lane EL, Brundin P, Cenci MA.
    Neurobiol Dis; 2009 Jul 01; 35(1):42-51. PubMed ID: 19361557
    [Abstract] [Full Text] [Related]

  • 7. Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
    Smith GA, Heuer A, Klein A, Vinh NN, Dunnett SB, Lane EL.
    J Parkinsons Dis; 2012 Jul 01; 2(2):107-13. PubMed ID: 23933747
    [Abstract] [Full Text] [Related]

  • 8. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
    Ikeda K, Yoshikawa S, Kurokawa T, Yuzawa N, Nakao K, Mochizuki H.
    Eur J Pharmacol; 2009 Oct 12; 620(1-3):42-8. PubMed ID: 19686730
    [Abstract] [Full Text] [Related]

  • 9. Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Kwan C, Frouni I, Bédard D, Hamadjida A, Huot P.
    Eur J Pharmacol; 2020 Mar 15; 871():172914. PubMed ID: 31926127
    [Abstract] [Full Text] [Related]

  • 10. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
    Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, Park JY, Bishop C.
    Psychopharmacology (Berl); 2008 Jul 15; 199(1):99-108. PubMed ID: 18545986
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model.
    Flores AJ, Bartlett MJ, So LY, Laude ND, Parent KL, Heien ML, Sherman SJ, Falk T.
    Neurosci Lett; 2014 Apr 03; 564():48-52. PubMed ID: 24525249
    [Abstract] [Full Text] [Related]

  • 12. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
    Takuma K, Tanaka T, Takahashi T, Hiramatsu N, Ota Y, Ago Y, Matsuda T.
    Eur J Pharmacol; 2012 May 15; 683(1-3):166-73. PubMed ID: 22449381
    [Abstract] [Full Text] [Related]

  • 13. AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
    Périer C, Marin C, Bonastre M, Tolosa E, Hirsch EC.
    Eur J Neurosci; 2002 Dec 15; 16(11):2236-40. PubMed ID: 12473092
    [Abstract] [Full Text] [Related]

  • 14. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Tronci E, Fidalgo C, Zianni E, Collu M, Stancampiano R, Morelli M, Gardoni F, Carta M.
    Neuroscience; 2014 Apr 18; 265():245-52. PubMed ID: 24486947
    [Abstract] [Full Text] [Related]

  • 15. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.
    Mov Disord; 2013 Jul 18; 28(8):1088-96. PubMed ID: 23389842
    [Abstract] [Full Text] [Related]

  • 16. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.
    Neuropharmacology; 2018 Mar 15; 131():116-127. PubMed ID: 29197517
    [Abstract] [Full Text] [Related]

  • 17. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb 15; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 18. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 15; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 19. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants.
    Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P.
    Sci Transl Med; 2010 Jun 30; 2(38):38ra46. PubMed ID: 20592420
    [Abstract] [Full Text] [Related]

  • 20. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC, Varney MA, Newman-Tancredi A.
    Neuropharmacology; 2016 Jun 30; 105():651-660. PubMed ID: 26777281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.